The efficacy of Withania somnifera on spermogram in infertile me
- Conditions
- Male Infertility.Diseases of male genital organs,Male infertility
- Registration Number
- IRCT2015092224135N1
- Lead Sponsor
- Vice chancellor for research,Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 100
Patient satisfaction? Men 18-45 years? Infertility for at least one year with unexplained Oligo+/- astheno +/- teratozoospermia according to WHO criteria? Nonsmoking and nonaddiction to alcohol and drugs? No azospermia? No infections, No genital anatomical abnormalities? No risk of varicocele? No history of surgery on the genital tract? No Systemic diseases ( cancer, thyroid diseases, liver and gall bladder diseases, renal failure, diabetes, uncontrolled hypertension, cerebral hemorrhage , retina bleeding, etc)? No unilateral testicular atrophy? No history of taking chemotherapy, corticosteroid, anticoagulation,testosterone, antiandrogen.
Exclusion criteria: Smoking or any kind of drug abuse during the study? Intaking any other chemical or herbal infertility drug during the study? Make any side effects from medication? The need for other interventions and surgery during the study? The reluctance of patients to continue.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sperm count. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Sperm analysis.;Sperm motility. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Semen analysis.;Sperm morphology. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Semen analysis.;Semen volume. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Semen analysis.
- Secondary Outcome Measures
Name Time Method To determine the potential adverse events resulting from treatment process in patients in the intervention groups. Timepoint: during the study. Method of measurement: questionnaire-Observation-reportage.